Kohjin Bio: Consolidated Financial Results for the 2nd Quarter (Interim Period) for the Fiscal Year Ending March 31, 2026 [Japanese GAAP] (Consolidated)

JPXNov 13, 2025 01:30 ET · Announcements

Kohjin Bio: Half Year Report - Term 45 (2025/04/01 - 2026/03/31)

EDINETNov 13, 2025 01:30 ET · Announcements

Express News | [Change Report] Gordian Capital Singapore Private Limited has reported an increase in its stake in Kojiin Bio (177A.JP) to 7.11%.

Moomoo NewsSep 7, 2025 22:43 ET

Afternoon Session [Active Stocks and Trading Volumes]

*Mitsubishi Motors Corporation <7211> revised its earnings forecast for the fiscal year ending March 2026 downward to 401.5 million yen.* S&B Foods <2805> announced a change in its shareholder benefit program, currently at 3,265 yen, up by 30 yen.* Genki GDC <9828> is acquiring two companies related to seafood, currently priced at 3,445 yen, up by 55 yen. The upside appears limited.* Cojin Bio <177A> is introducing technology related to artificial skin through technology transfer and a licensing agreement for patent rights, currently valued at 1,755 yen, up by 33 yen. The upside is restricted.* Enechange <4169> experienced a decrease of 42 yen to 379 yen, reflecting a correction after a significant rise the previous day.

Fisco JapanAug 27, 2025 03:10 ET

Koijin B is listed with a buy recommendation, having entered into a contract with OrganTech for technology transfer and licensing of patent rights related to artificial skin technology.

Kojin Bio <177A.T> is showing a buy indication. On the afternoon of the 27th, it announced that it had concluded a contract with OrganTech (Chuo-ku, Tokyo) regarding the technology transfer and licensing of patent rights related to artificial skin technology, which has garnered buying interest. OrganTech is a biotechnology company focused on organ regeneration medicine and possesses proprietary technology for creating human three-dimensional artificial skin models for research support. With this technology transfer, OrganTech will develop a research support three-dimensional human...

Kabushiki ShimbunAug 27, 2025 00:10 ET

Dentsu Group has revised its operating loss downward to ▲3.5 billion yen from 66 billion yen.

Dentsu Group <4324> has announced a revision to its Financial Estimates for the fiscal year ending December 2025. The company has revised its operating profit forecast from a 660 billion yen surplus to a 35 billion yen deficit. This revision is due to impairment losses on goodwill related to the United States and EMEA regions. For the first half of the fiscal year ending December 2025, revenue increased by 0.4% year-over-year to 683.94 billion yen, while the operating loss was 36.545 billion yen (compared to a 25.73 billion yen profit in the same period of the previous year). [Positive Evaluation] <6361> E

Fisco JapanAug 14, 2025 16:05 ET